These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 20178102)

  • 1. Cancer antineovascular therapy with liposome drug delivery systems targeted to BiP/GRP78.
    Katanasaka Y; Ishii T; Asai T; Naitou H; Maeda N; Koizumi F; Miyagawa S; Ohashi N; Oku N
    Int J Cancer; 2010 Dec; 127(11):2685-98. PubMed ID: 20178102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel DDS strategy, "dual-targeting", and its application for antineovascular therapy.
    Murase Y; Asai T; Katanasaka Y; Sugiyama T; Shimizu K; Maeda N; Oku N
    Cancer Lett; 2010 Jan; 287(2):165-71. PubMed ID: 19616372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective delivery of an angiogenesis inhibitor by neovessel-targeted liposomes.
    Katanasaka Y; Ida T; Asai T; Maeda N; Oku N
    Int J Pharm; 2008 Aug; 360(1-2):219-24. PubMed ID: 18565703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, SU5416.
    Katanasaka Y; Ida T; Asai T; Shimizu K; Koizumi F; Maeda N; Baba K; Oku N
    Cancer Lett; 2008 Nov; 270(2):260-8. PubMed ID: 18555591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase.
    Kondo M; Asai T; Katanasaka Y; Sadzuka Y; Tsukada H; Ogino K; Taki T; Baba K; Oku N
    Int J Cancer; 2004 Jan; 108(2):301-6. PubMed ID: 14639619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucose-regulated protein 78 silencing down-regulates vascular endothelial growth factor/vascular endothelial growth factor receptor 2 pathway to suppress human colon cancer tumor growth.
    Kuo LJ; Hung CS; Chen WY; Chang YJ; Wei PL
    J Surg Res; 2013 Nov; 185(1):264-72. PubMed ID: 23759331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted delivery of small interfering RNA to angiogenic endothelial cells with liposome-polycation-DNA particles.
    Vader P; Crielaard BJ; van Dommelen SM; van der Meel R; Storm G; Schiffelers RM
    J Control Release; 2012 Jun; 160(2):211-6. PubMed ID: 21983283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronopharmacologic cancer treatment with an angiogenic vessel-targeted liposomal drug.
    Shimizu K; Sawazaki Y; Tanaka T; Asai T; Oku N
    Biol Pharm Bull; 2008 Jan; 31(1):95-8. PubMed ID: 18175949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A therapeutically relevant, 3,3'-diindolylmethane derivative NGD16 attenuates angiogenesis by targeting glucose regulated protein, 78kDa (GRP78).
    Nayak D; Amin H; Rah B; Ur Rasool R; Sharma D; Gupta AP; Kushwaha M; Mukherjee D; Goswami A
    Chem Biol Interact; 2015 May; 232():58-67. PubMed ID: 25794856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arg-Leu-Tyr-Glu tetrapeptide inhibits tumor progression by suppressing angiogenesis and vascular permeability via VEGF receptor-2 antagonism.
    Baek YY; Lee DK; Kim J; Kim JH; Park W; Kim T; Han S; Jeoung D; You JC; Lee H; Won MH; Ha KS; Kwon YG; Kim YM
    Oncotarget; 2017 Feb; 8(7):11763-11777. PubMed ID: 28052029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumor actions of major component 3'-O-acetylhamaudol of Angelica japonica roots through dual actions, anti-angiogenesis and intestinal intraepithelial lymphocyte activation.
    Kimura Y; Sumiyoshi M; Baba K
    Cancer Lett; 2008 Jun; 265(1):84-97. PubMed ID: 18358599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomics of human umbilical vein endothelial cells applied to etoposide-induced apoptosis.
    Bruneel A; Labas V; Mailloux A; Sharma S; Royer N; Vinh J; Pernet P; Vaubourdolle M; Baudin B
    Proteomics; 2005 Oct; 5(15):3876-84. PubMed ID: 16130169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3'-kinase activity.
    Bagli E; Stefaniotou M; Morbidelli L; Ziche M; Psillas K; Murphy C; Fotsis T
    Cancer Res; 2004 Nov; 64(21):7936-46. PubMed ID: 15520200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
    Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
    Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applicability of anti-neovascular therapy to drug-resistant tumor: suppression of drug-resistant P388 tumor growth with neovessel-targeted liposomal adriamycin.
    Shimizu K; Asai T; Fuse C; Sadzuka Y; Sonobe T; Ogino K; Taki T; Tanaka T; Oku N
    Int J Pharm; 2005 May; 296(1-2):133-41. PubMed ID: 15885465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced cancer therapy by integrative antitumor actions via systemic administration of miR-499.
    Ando H; Asai T; Koide H; Okamoto A; Maeda N; Tomita K; Dewa T; Minamino T; Oku N
    J Control Release; 2014 May; 181():32-9. PubMed ID: 24593893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
    Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
    Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
    Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orally Administered Mucolytic Drug l-Carbocisteine Inhibits Angiogenesis and Tumor Growth in Mice.
    Shinya T; Yokota T; Nakayama S; Oki S; Mutoh J; Takahashi S; Sato K
    J Pharmacol Exp Ther; 2015 Sep; 354(3):269-78. PubMed ID: 26126534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.